Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2015-07-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于筹划非公开发行股票事项停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the progress of a planned non-public issuance of shares, including details about the stock suspension and intended use of funds. It is not a full financial report but an update on capital raising activities. The document length is short (600 characters), and it is an announcement about financing plans and stock suspension, fitting the Capital/Financing Update category rather than a full report or regulatory filing.
2015-07-17 Chinese
2015年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2015, indicating expected net profit and earnings per share, with a note that the forecast is unaudited and preliminary. It explicitly states that the final data will be in the 2015 half-year report. This is a typical earnings forecast or earnings guidance document, not the actual interim report itself. The document length is short (615 characters), and it is an announcement of expected financial results rather than containing actual financial statements or detailed analysis. Therefore, it fits best under Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2015
2015-07-14 Chinese
关于筹划非公开发行股票事项停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the company's stock suspension due to planning a non-public stock issuance. It mentions the company's application to the Shenzhen Stock Exchange for a trading halt and updates on the progress of the non-public stock issuance. There are no financial statements, detailed financial data, or comprehensive report content. The document is an update on capital raising activities and stock suspension related to financing. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and focused on financing progress, not a full report or regulatory filing.
2015-07-10 Chinese
关于筹划非公开发行股票事项停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the progress of a trading suspension due to planning a non-public issuance of shares. It mentions the company's stock suspension and fundraising plans but does not contain financial statements or detailed financial data. The content focuses on capital raising activities and stock issuance plans, which aligns with updates on financing activities or capital structure changes. The document length is short (493 characters), and it is not a report but an announcement about ongoing capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-07-05 Chinese
关于筹划非公开发行股票事项停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a company about the progress of a planned non-public stock issuance, including details about the stock suspension and expected timeline for disclosure. It does not contain financial statements or detailed financial data, but rather updates on the capital raising process and stock trading suspension. The document length is only 553 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits the category of Capital/Financing Update (CAP).
2015-06-26 Chinese
关于诉讼事项终审结果的公告
Legal Proceedings Report Classification · 100% confidence The document is an announcement regarding the final judgment of a litigation case involving the company. It details the background of the lawsuit, the court decisions at various stages, and the final ruling by the Beijing Second Intermediate People's Court. There is no financial data, no report attached or referenced as being published, and the content focuses solely on legal proceedings and their impact on the company. Therefore, this document fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification, so it is not RPA or RNS.
2015-06-25 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.